title: Tranexamic acid in hip fracture patients: a protocol for a randomised, placebo controlled trial on the efficacy of tranexamic acid in reducing blood loss in hip fracture patients.
abstract: There is a high incidence of blood transfusion following hip fractures in elderly patients. Tranexamic acid (TXA) has proven efficacy in decreasing blood loss in general trauma patients as well as patients undergoing elective orthopaedic surgery. A randomised controlled trial will measure the effect of TXA in a population of patients undergoing hip fracture surgery.
  
  
  
  This is a double-blinded, randomised placebo-controlled trial. Patients admitted through the emergency room that are diagnosed with an intertrochanteric or femoral neck fracture will be eligible for enrolment and randomised to either treatment with 1 g of intravenous TXA or intravenous saline at the time of skin incision. Patients undergoing percutaneous intervention for non-displaced or minimally displaced femoral neck fractures will not be eligible for enrolment. Postoperative transfusion rates will be recorded and blood loss will be calculated from serial haematocrits.
  
  
  
  This protocol was approved by the Institutional Review Board (IRB) and is registered with clinicaltrials.gov. The findings of the trial will be disseminated through peer-reviewed journals and conference presentations.
  
  
  
  NCT01940536.
authors.affiliation: Department of Orthopaedics, Hospital for Special Surgery, New York, New York, USA.
authors.forename: Elizabeth Bishop
authors.initials: EB
authors.lastname: Gausden
authors.affiliation: Department of Orthopaedics, Harborview Medical Center, Seattle, Washington, USA.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Garner
authors.affiliation: Department of Orthopaedics, Hospital for Special Surgery, New York, New York, USA.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Warner
authors.affiliation: Department of Orthopaedics, Hospital for Special Surgery, New York, New York, USA.
authors.forename: Ashley
authors.initials: A
authors.lastname: Levack
authors.affiliation: Department of Orthopaedic Trauma, New York Presbyterian Hospital, New York, New York, USA.
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Nellestein
authors.affiliation: Department of Anesthesiology, New York Presbyterian Hospital, New York, New York, USA.
authors.forename: Tiffany
authors.initials: T
authors.lastname: Tedore
authors.affiliation: Department of Internal Medicine, New York Presbyterian Hospital, New York, New York, USA.
authors.forename: Eva
authors.initials: E
authors.lastname: Flores
authors.affiliation: Department of Orthopaedic Trauma, New York Presbyterian Hospital, New York, New York, USA.
authors.forename: Dean G
authors.initials: DG
authors.lastname: Lorich
mesh_terms: D000368:Aged; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D002985:Clinical Protocols; D004311:Double-Blind Method; D005260:Female; D006620:Hip Fractures / Q000150:complications / Q000601:surgery*; D006801:Humans; D014148:Tranexamic Acid / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid
keywords: blood transfusion; hip fracture; tranexamic acid